TY - CHAP
T1 - Components of the plasminogen-plasmin system as biologic markers for cancer
AU - McMahon, Brandon J.
AU - Kwaan, Hau C.
N1 - Publisher Copyright:
© Springer Science+Business Media Dordrecht 2015 145.
PY - 2015
Y1 - 2015
N2 - Members of the plasminogen-plasmin (PP) system participate in many physiologic functions. In particular, uPA, its receptor (uPAR) and its inhibitor PAI-1 play an important role in cell migration, cell proliferation and tissue remodeling. Through a number of interactions, these components of the PP system are also involved in the pathogenesis of many diseases. In cancer, they modulate the essential processes of tumor development, growth, invasion and metastasis as well as angiogenesis and fi brosis. Thus, quantifi cation of uPA, uPAR and PAI-1 in tumors and, in some cases in the circulating blood, became of potential value in the prognostication of many types of cancer. These include cancer of the breast, stomach, colon and rectum, esophagus, pancreas, glioma, lung, kidney, prostate, uterine cervix, ovary, liver and bone. Published data are reviewed in this chapter. Clinical validation of the prognostic value has also been made, particularly in cancer of the breast. Inclusion of these biomarkers in the risk assessment of cancer patients is now considered in the risk-adapted management in carcinoma of the breast. Factors limiting its broader use are discussed with suggestions how these can be overcome. Hopefully the use of these biomarkers will be applied to other types of cancer in the near future.
AB - Members of the plasminogen-plasmin (PP) system participate in many physiologic functions. In particular, uPA, its receptor (uPAR) and its inhibitor PAI-1 play an important role in cell migration, cell proliferation and tissue remodeling. Through a number of interactions, these components of the PP system are also involved in the pathogenesis of many diseases. In cancer, they modulate the essential processes of tumor development, growth, invasion and metastasis as well as angiogenesis and fi brosis. Thus, quantifi cation of uPA, uPAR and PAI-1 in tumors and, in some cases in the circulating blood, became of potential value in the prognostication of many types of cancer. These include cancer of the breast, stomach, colon and rectum, esophagus, pancreas, glioma, lung, kidney, prostate, uterine cervix, ovary, liver and bone. Published data are reviewed in this chapter. Clinical validation of the prognostic value has also been made, particularly in cancer of the breast. Inclusion of these biomarkers in the risk assessment of cancer patients is now considered in the risk-adapted management in carcinoma of the breast. Factors limiting its broader use are discussed with suggestions how these can be overcome. Hopefully the use of these biomarkers will be applied to other types of cancer in the near future.
KW - Biomarker
KW - Cancer
KW - PAI-1
KW - Thrombosis
KW - uPA
KW - uPA /PAI-1 in breast cancer
KW - uPA activity and lymph node involvement
KW - uPA and PAI-1 expression
KW - uPA/PAI-1 as biomarkers
KW - uPAR
UR - http://www.scopus.com/inward/record.url?scp=84946925571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946925571&partnerID=8YFLogxK
U2 - 10.1007/978-94-017-7215-0_10
DO - 10.1007/978-94-017-7215-0_10
M3 - Chapter
C2 - 26530365
AN - SCOPUS:84946925571
T3 - Advances in Experimental Medicine and Biology
SP - 145
EP - 156
BT - Advances in Experimental Medicine and Biology
PB - Springer New York LLC
ER -